These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 11641415)
1. Characterization of a human colorectal carcinoma cell line with acquired resistance to flavopiridol. Smith V; Raynaud F; Workman P; Kelland LR Mol Pharmacol; 2001 Nov; 60(5):885-93. PubMed ID: 11641415 [TBL] [Abstract][Full Text] [Related]
2. Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor. Incles CM; Schultes CM; Kelland LR; Neidle S Mol Pharmacol; 2003 Nov; 64(5):1101-8. PubMed ID: 14573759 [TBL] [Abstract][Full Text] [Related]
3. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Raju U; Nakata E; Mason KA; Ang KK; Milas L Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657 [TBL] [Abstract][Full Text] [Related]
4. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881 [TBL] [Abstract][Full Text] [Related]
5. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Motwani M; Li X; Schwartz GK Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717 [TBL] [Abstract][Full Text] [Related]
6. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540 [TBL] [Abstract][Full Text] [Related]
7. Characterization of an ovarian carcinoma cell line resistant to cisplatin and flavopiridol. Bible KC; Boerner SA; Kirkland K; Anderl KL; Bartelt D; Svingen PA; Kottke TJ; Lee YK; Eckdahl S; Stalboerger PG; Jenkins RB; Kaufmann SH Clin Cancer Res; 2000 Feb; 6(2):661-70. PubMed ID: 10690552 [TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer. Chien M; Astumian M; Liebowitz D; Rinker-Schaeffer C; Stadler WM Cancer Chemother Pharmacol; 1999; 44(1):81-7. PubMed ID: 10367753 [TBL] [Abstract][Full Text] [Related]
9. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Jung CP; Motwani MV; Schwartz GK Clin Cancer Res; 2001 Aug; 7(8):2527-36. PubMed ID: 11489836 [TBL] [Abstract][Full Text] [Related]
10. Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line. Smith V; Rowlands MG; Barrie E; Workman P; Kelland LR Clin Cancer Res; 2002 Jun; 8(6):2002-9. PubMed ID: 12060646 [TBL] [Abstract][Full Text] [Related]
11. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031 [TBL] [Abstract][Full Text] [Related]
12. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Robey RW; Medina-Pérez WY; Nishiyama K; Lahusen T; Miyake K; Litman T; Senderowicz AM; Ross DD; Bates SE Clin Cancer Res; 2001 Jan; 7(1):145-52. PubMed ID: 11205902 [TBL] [Abstract][Full Text] [Related]
13. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia. Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730 [TBL] [Abstract][Full Text] [Related]
14. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Schrump DS; Matthews W; Chen GA; Mixon A; Altorki NK Clin Cancer Res; 1998 Nov; 4(11):2885-90. PubMed ID: 9829756 [TBL] [Abstract][Full Text] [Related]
15. The cyclin-dependent kinase inhibitor flavopiridol potentiates gamma-irradiation-induced apoptosis in colon and gastric cancer cells. Jung C; Motwani M; Kortmansky J; Sirotnak FM; She Y; Gonen M; Haimovitz-Friedman A; Schwartz GK Clin Cancer Res; 2003 Dec; 9(16 Pt 1):6052-61. PubMed ID: 14676132 [TBL] [Abstract][Full Text] [Related]
16. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955 [TBL] [Abstract][Full Text] [Related]
17. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Camphausen K; Brady KJ; Burgan WE; Cerra MA; Russell JS; Bull EE; Tofilon PJ Mol Cancer Ther; 2004 Apr; 3(4):409-16. PubMed ID: 15078984 [TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Mayer F; Mueller S; Malenke E; Kuczyk M; Hartmann JT; Bokemeyer C Invest New Drugs; 2005 Jun; 23(3):205-11. PubMed ID: 15868376 [TBL] [Abstract][Full Text] [Related]
19. Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Raju U; Ariga H; Koto M; Lu X; Pickett J; Valdecanas D; Mason KA; Milas L Radiother Oncol; 2006 Aug; 80(2):185-91. PubMed ID: 16905211 [TBL] [Abstract][Full Text] [Related]